Skip to main content
. 2021 Jul 28;53:101312. doi: 10.1016/j.molmet.2021.101312

Figure 5.

Figure 5

Rax-CreERT2:ArcPomcloxTB/loxTBmice show significantly reduced fat mass compared to ArcPomcloxTB/loxTBmice. (A, H) Bodyweight growth curves of males and females following TAM treatment. There was no significant change in bodyweight between ArcPomcloxTB/loxTB and Rax-CreERT2:ArcPomcloxTB/loxTB mice over 16 weeks (p > 0.05, one-way ANOVA; Tukey's multiple comparisons). Body composition - Fat mass (B, I); lean mass (C, J); and fluid mass (D, K) of male (B–D) and female (I–K) mice analyzed by NMR. (E-G, L-N) Body composition mass measurements are shown as a percentage of total body mass. Rax-CreERT2/+:ArcPomcloxTB/loxTB mice show reduced fat mass (males: p = 0.05, females: ∗∗p = 0.007; Tukey's multiple comparisons), and reduced fat mass% in males (∗∗∗p = 0.0009; Tukey's multiple comparisons) compared to ArcPomcloxTB/loxTB mice. Data are shown as mean ± SEM (males, n = 6–9/group; females, n = 3–8/group). Individual mouse values are represented by filled circles. The data were analyzed using one-way ANOVA followed by Tukey's multiple comparisons test.